Search Results: Patent Dance

Amgen’s Motion to Dismiss Genentech’s Complaint in the Delaware Mvasi Litigation

As we previously reported, Genentech has filed two pending cases (Case Nos. 1:17-cv-01407 and 1:17-cv-01471) in the District of Delaware related to Amgen’s proposed Mvasi (bevacizumab-awwb), a biosimilar of Genentech’s Avastin.  On December 6, 2017, Genentech filed a sealed amended and supplemental complaint in Case No. 1:17-cv-01407, and on December 13, Genentech filed a redacted version.  Last month Amgen…

Read More

Goodwin's Guide to the Biosimilars Patent Dance

Goodwin released today its Guide to the Biosimilars Patent Dance, which lays out in a user-friendly format the complex statutory scheme of the so-called “patent dance” codified in subsection 262(l) of the Biologics Competition and Innovation Act (BPCIA).  The BPCIA’s patent dance dictates a schedule of timed steps according to…

Read More